Related Experiment Video

Updated: Aug 1, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

Developing effective therapeutics for Alzheimer's disease -- emerging mechanisms and actions in translational

Can Zhang1

  • 1Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.

Discovery Medicine
|April 4, 2017
PubMed

Insights

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no current disease-modifying therapies. Research highlights amyloid-beta (Aβ) and tau pathology, neuro-inflammation, and risk factors as key mechanisms for developing new Alzheimer's treatments.

Area of Science:

  • Neuroscience
  • Pathology
  • Genetics

Background:

  • Alzheimer's disease (AD) is an irreversible neurodegenerative disorder with no effective disease-modifying treatments.
  • While early-onset AD is linked to specific gene mutations, the causes of late-onset AD remain unclear.
  • Current research focuses on understanding AD's pathological mechanisms.

Purpose of the Study:

  • To review emerging mechanisms in Alzheimer's disease (AD) pathogenesis.
  • To discuss novel therapeutic approaches in translational medicine for AD.
  • To highlight the roles of amyloid-beta (Aβ), tau pathology, and neuro-inflammation.

Main Methods:

  • Literature review of recent research on Alzheimer's disease.
  • Analysis of emerging mechanisms in AD pathogenesis, including Aβ and tau pathology.
  • Characterization of modifiable risk factors associated with AD.

Main Results:

  • Emerging mechanisms, including amyloid-beta (Aβ) and tau pathology, are central to AD pathogenesis.
  • Neuro-inflammation and modifiable risk factors play significant roles in AD development.
  • Understanding these mechanisms facilitates the development of new AD therapeutics.

Conclusions:

  • Significant progress has been made in understanding AD's underlying mechanisms.
  • Emerging insights into Aβ, tau pathology, and neuro-inflammation offer therapeutic targets.
  • Translational medicine approaches are advancing the development of effective AD treatments.

More Related Videos

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...